The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -2.59 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as ACCENDRA HEALTH INC/VA/ reports it. History and quarterly detail are in the app.
- Diabetes Product$783.4M
- Sleep Therapy Product$740.1M
- Home Respiratory Therapy Product$433.1M
- Product And Service Other$288.2M
- Ostomy$212.8M
Leadership changes
From ACCENDRA HEALTH INC/VA/'s own filings, the day they're filed.
- Perry A. Bernocchi · President · appointmenteff. 2025-12-05
- Jonathan A. Leon · President · appointmenteff. 2024-09-23
- Jonathan A. Leon · Chief Financial Officer · appointmenteff. 2024-06-21
Latest filings
- 8-K · Company announcement2026-06-25
- 8-K · Company announcement2026-06-15
- 8-K · Company announcement2026-05-22
- 8-K · Company announcement2026-05-15
- 10-Q · Quarterly report2026-05-11
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about ACCENDRA HEALTH INC/VA/, every answer cited🔒
- The Intelligence Brief — added when ACCENDRA HEALTH INC/VA/'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.